Why the study?
ACS-induced PTSD may increase secondary CVD risk, but prior studies were small and underpowered to test plausible behavioral or biological mechanisms.
Does ACS-induced PTSD increase the risk of recurrent CVD events and mortality in patients presenting with ACS symptoms?
Does ACS-induced PTSD increase the risk of recurrent CVD events and mortality in patients presenting with ACS symptoms?
The ReACH study will prospectively evaluate whether ACS-induced PTSD increases the risk of recurrent cardiovascular events and mortality, and if medication adherence mediates this association.
AIMS: As many as 1 in 8 acute coronary syndrome (ACS) patients develop posttraumatic stress disorder (PTSD) due to the ACS, and ACS-induced PTSD may increase secondary cardiovascular disease (CVD) risk. However, prior studies have been small and underpowered to test plausible behavioral or biological mechanisms of the hypothesized PTSD-secondary CVD risk association. In this paper, we describe the design and methods of a large prospective observational cohort study to estimate the prognostic significance of ACS-induced PTSD, mechanisms for its association with CVD risk, and emergency department (ED) factors that may increase PTSD risk, in a cohort of patients evaluated for acute coronary syndrome (ACS) in the ED of a large, urban academic medical center. METHODS: The Reactions to Acute Care and Hospitalization (ReACH) study follows 1,741 racially, ethnically, and socioeconomically diverse patients initially presenting to the ED with ACS symptoms. Psychosocial factors are assessed at baseline. Medication adherence is monitored by electronic pill bottle (eCAP). Participants are contacted by phone at 1-, 6-, and 12-months post-hospitalization to assess PTSD symptoms, hospital readmission, and recurrent CVD events/mortality (proactively searched and confirmed by medical records). CONCLUSION: This study will provide the most accurate estimates to date of PTSD's association with recurrent CVD events and mortality and will test whether medication adherence mediates that association. Further, it will provide estimates of the contribution of ED and hospital factors to PTSD risk in ACS patients. If our hypotheses are supported, we will have identified PTSD as a novel target for secondary risk reduction.
No takes yet. Share an insight, caveat, or question.
Birk et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: